secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001193125-22-302256
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen to acquire Horizon Therapeutics for $116.50/share; $28.5B bridge facility arranged
--------------------------------------------------------------------------------

- Cash offer of $116.50 per Horizon share; transaction unanimously recommended by Horizon Board.
- Closing expected first half of 2023, subject to Horizon shareholder, Irish court, and regulatory approvals.
- Bridge credit facility of $28.5B entered to finance consideration and repay Horizon debt.
- Amgen pays ~$974M termination fee under certain regulatory failure scenarios.
- Conditions include antitrust clearances in US, Austria, Germany; foreign investment in France, Germany, Denmark, Italy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000119312522302256/0001193125-22-302256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000119312522302256/d346985d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-302256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer